Lifecore Biomedical Q2 2023 Earnings Report $5.91 -0.96 (-13.97%) As of 01/7/2025 04:00 PM Eastern Earnings HistoryForecast Lifecore Biomedical EPS ResultsActual EPS-$0.24Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALifecore Biomedical Revenue ResultsActual Revenue$38.80 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALifecore Biomedical Announcement DetailsQuarterQ2 2023Date3/16/2023TimeN/AConference Call ResourcesPress ReleaseLFCR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by $2 Trillion Disappears Because of Fed's Secretive New Move (Ad)$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.Click here to see his new research now. Lifecore Biomedical Earnings HeadlinesLifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 MillionJanuary 7 at 9:00 AM | globenewswire.comLifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6 at 4:05 PM | globenewswire.comVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.January 8, 2025 | Porter & Company (Ad)Stephens Reiterates "Equal Weight" Rating for Lifecore Biomedical (NASDAQ:LFCR)January 5 at 3:19 AM | americanbankingnews.comLifecore Biomedical, Inc. (NASDAQ:LFCR) Q2 2025 Earnings Call TranscriptJanuary 4, 2025 | insidermonkey.comStocks to Watch: Lifecore Biomedical, Resources ConnectionJanuary 4, 2025 | marketwatch.comSee More Lifecore Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lifecore Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lifecore Biomedical and other key companies, straight to your email. Email Address About Lifecore BiomedicalLifecore Biomedical (NASDAQ:LFCR), together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.View Lifecore Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
